Holen Sie sich die Stockscreener-App
1.49
2.61%
-0.04
Handel nachbörslich:
1.54
0.05
+3.36%
Schlusskurs vom Vortag:
$1.53
Offen:
$1.51
24-Stunden-Volumen:
496.55K
Relative Volume:
1.21
Marktkapitalisierung:
$8.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.76M
KGV:
-18.62
EPS:
-0.08
Netto-Cashflow:
$-132.97M
1W Leistung:
+1.36%
1M Leistung:
-44.19%
6M Leistung:
-89.82%
1J Leistung:
-93.77%
1-Tages-Spanne:
$1.45
$1.518
1-Wochen-Bereich:
$1.38
$1.71
52-Wochen-Spanne:
$1.38
$26.96
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Firmenname
X 4 Pharmaceuticals Inc
Sektor
Branche
Telefon
857-529-8300
Adresse
61 NORTH BEACON STREET, BOSTON, MA
Vergleichen Sie XFOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
1.49 | 10.55M | 0 | -16.76M | -132.97M | -0.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-12 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-12-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-12-05 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-07 | Eingeleitet | Stifel | Buy |
| 2019-06-05 | Eingeleitet | Cowen | Outperform |
Alle ansehen
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
Is X4 Pharmaceuticals Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com
Why X4 Pharmaceuticals Inc. stock attracts strong analyst attentionSafety First Trading Signals - Newser
What drives X4 Pharmaceuticals Inc. stock priceUnstoppable profit momentum - jammulinksnews.com
Trump tariffs live updates: Prospects for India, EU deals falter as Trump pushes for higher tariffs - Yahoo Finance
What analysts say about X4 Pharmaceuticals Inc. stockAccelerated investment success - Autocar Professional
X4 Pharmaceuticals Inc. Stock Analysis and ForecastExceptional profit margins - Autocar Professional
Bronze Infra (534731) Hits 52 Week HighTremendous growth potential - Autocar Professional
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results - The Manila Times
What analysts say about X4 Pharmaceuticals Inc. stock outlookFree Best Stocks to Buy Today - beatles.ru
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
Top Stocks for Indian Stock Market in 2025 Top Stocks Chosen By ExpertsBreakout stock performance - Jammu Links News
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold? - TradingView
XFOR’s 2025 Market Dance: Down -92.95% – Time to Invest? - investchronicle.com
Windtree Makes Historic Move: Secures $60M to Become First NASDAQ-Listed BNB Crypto Player - Stock Titan
Fierce Biotech Layoff Tracker 2025: Sarepta lays off 500 staffers; GSK trims R&D team - Fierce Biotech
What makes X4 Pharmaceuticals Inc. stock price move sharplyHigh Return Potential - Newser
How X4 Pharmaceuticals Inc. stock performs during market volatilityHigh Reward Risk Balanced Trading - Newser
Milestone Pharmaceuticals Public Offering Aims to Accelerate Breakthrough PSVT Treatment Launch - Stock Titan
FDA Sets New December 2025 Decision Date for Milestone's PSVT Nasal Spray, Secures $75M Funding - Stock Titan
MIST gets FDA review nod; PDUFA set for Dec 13 2025 – covenant aligned | MIST SEC FilingForm 8-K - Stock Titan
European Undervalued Small Caps With Insider Action For July 2025 - Yahoo Finance
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade - Business Wire
Hyperparathyroidism Pipeline 2025: Groundbreaking Clinical - openPR.com
Breakthrough Brain Cancer Treatment: FDA Backs Mustang Bio Therapy After 66-Month Complete Response in Trials - Stock Titan
UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc. - ACCESS Newswire
Form 424B5 X4 Pharmaceuticals, Inc - StreetInsider
Top 10 pharma companies in India by market cap [2025] - Forbes India
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 27.1% in May - Defense World
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association - MarketScreener
Unicycive Sets 1-for-10 Reverse Split: What This Means for 126M Outstanding Shares - Stock Titan
China pharma projects disrupted by Sino-US tensions - Reuters
XFOR Presents Positive Phase 2 Trial Results for Mavorixafor at EHA Congress | XFOR Stock News - GuruFocus
X4 Pharmaceuticals presents positive data from neutropenia trial By Investing.com - Investing.com Canada
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) - marketscreener.com
Finanzdaten der X 4 Pharmaceuticals Inc-Aktie (XFOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):